Quantcast

Impact of left ventricular remodelling patterns on outcomes in patients with aortic stenosis.

Research paper by Romain R Capoulade, Marie-Annick MA Clavel, Florent F Le Ven, Abdellaziz A Dahou, Christophe C Thébault, Lionel L Tastet, Mylène M Shen, Marie M Arsenault, Élisabeth É Bédard, Jonathan J Beaudoin, Kim K O'Connor, Mathieu M Bernier, Jean G JG Dumesnil, Philippe P Pibarot

Indexed on: 09 Jan '17Published on: 09 Jan '17Published in: European heart journal cardiovascular Imaging



Abstract

The objective of this study was to examine the association between the different patterns of left ventricular (LV) remodelling/hypertrophy on all-cause and cardiovascular mortality in patients with aortic stenosis (AS).In total, 747 consecutive patients (69 ± 14 years, 57% men) with AS and preserved LV ejection fraction were included in this study. According to LV mass index and relative wall thickness, patients were classified into four LV patterns: normal, concentric remodelling (CR), concentric hypertrophy (CH), and eccentric hypertrophy (EH). One hundred and sixteen patients (15%) had normal pattern, 66 (9%) had EH, 169 (23%) had CR, and 396 (53%) had CH. During a median follow-up of 6.4 years, 339 patients died (242 from cardiovascular causes). CH was associated with higher risk of all-cause mortality compared with the three other LV patterns (all P < 0.05). After multivariable adjustment, CH remained associated with higher risk of mortality (HR = 1.27, 95% CI 1.01-1.61, P = 0.046). There was a significant interaction (P < 0.05) between sex and CH with regards to the impact on mortality: CH was associated with worse outcome in women (P = 0.0001) but not in men (P = 0.22). In multivariable analysis, CH remained associated with higher risk of worse outcome in women (HR = 1.56, 95% CI 1.08-2.24, P = 0.018).This study shows that CH was independently associated with increased risk of mortality in AS patients with preserved ejection fraction. This association was observed in women but not in men. The pattern of LV remodelling/hypertrophy should be integrated in the risk stratification process in patients with AS.